GC and GC Biopharma Both Earn A Ratings in KCGS ESG Evaluation

"Strengthen ESG management capabilities across the group"

GC (GC Holdings) and GC Biopharma said on November 13 that both received an overall A rating in the 2026 KCGS ESG Evaluation announced by the Korea Institute of Corporate Governance and Sustainability (KCGS).

KCGS is a leading ESG rating agency in Korea. Each year, it assesses the sustainability management practices of domestic listed companies in the areas of environment (E), social (S), and governance (G), and announces their ESG ratings.

GC Biopharma headquarters in Yongin, Gyeonggi Province. GC

In this year's evaluation, GC received an overall A rating, one grade higher than its B+ rating the previous year. In particular, its governance rating rose two grades, from B to A. GC Biopharma received an overall A rating for the second consecutive year. Its social rating rose one grade, from A to A+, and its governance rating also rose one grade, from B+ to A.

A company representative said, "We will continue to strengthen ESG management capabilities across the group and build trust with key stakeholders through sustainable management that meets global standards."

This content was produced with the assistance of AI translation services.